Pharmaceutical regulation of telomerase and its clinical potential
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Introduction Telomerase inhibitors Telomerase activators Conclusions and perspectives Telomeres serve the dual function of protecting chromosomes from genomic instability as well as protecting the ends of chromosomes from DNA damage machinery. The enzyme responsible for telomere maintenance is telomerase, an enzyme capable of reverse transcription. Telomerase activity is typically limited to specific cell types. However, telomerase activation in somatic cells serves as a key step toward cell immortalization and cancer. Targeting telomerase serves as a potential cancer treatment with significant therapeutic benefits. Beyond targeting cancers by inhibiting telomerase, manipulating the regulation of telomerase may also provide therapeutic benefit to other ailments, such as those related to aging. This review will introduce human telomeres and telomerase and discuss pharmacological regulation of telomerase, including telomerase inhibitors and activators, and their use in human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and function of telomeres
Blackburn, E. H. (1991) · Nature · doi:10.1038/350569a0 · Cited by 3,596
Shelterin: the protein complex that shapes and safeguards human telomeres
de Lange, T. (2005) · Genes & Development · doi:10.1101/gad.1346005 · Cited by 3,056 · cited 1×
“Shelterin is comprised of 6 individual proteins: TRF1 (Telomere Repeat Binding Factor 1), TRF2 (Telomere Repeat Binding Factor 2), RAP1 (Repressor/Activator Protein 1), POT1 (Protection of Telomeres 1), TIN2 (TRF1 interacting nuclear factor 2), and TPP1(also known as adrenocortical dysplasia homolog-mouse; TINT1, “TIN…”
Mammalian Telomeres End in a Large Duplex Loop
Griffith, J. D., Comeau, L., Rosenfield, S., Stansel, R. M., Bianchi, A., Moss, H., & de Lange, T. (1999) · Cell · doi:10.1016/s0092-8674(00)80760-6 · Cited by 2,447 · cited 1×
“It accomplishes this by folding upon itself forming a higher order structure known as the t-loop [9, 10].”
BackgroundThe RNA Component of Human Telomerase
Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) · Science · doi:10.1126/science.7544491 · Cited by 2,227 · cited 1×
“The telomerase RNA template (hTR or hTERC) contains a complementary sequence to the human telomere that serves as the base for replication of the telomere repeat sequence [20, 21].”
BackgroundMorin, G. B. (1989) · Cell · doi:10.1016/0092-8674(89)90035-4 · Cited by 1,495 · cited 1×
“The extension of telomeres is completed through the catalytic enzyme, telomerase reverse transcriptase (hTERT) [19, 22].”
BackgroundTelomeres and telomerase in cancer
Artandi, S. E., & DePinho, R. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp268 · Cited by 823 · cited 1×
“For example, components of the telomerase complex are upregulated in over 90% of human malignancies and contribute to the increased proliferation and limitless replicative potential of cancer cells [30–33].”
BackgroundSpeakman, J. R., Talbot, D. A., Selman, C., Snart, S., McLaren, J. S., Redman, P., Krol, E., Jackson, D. M., Johnson, M. S., & Brand, M. D. (2004) · Aging Cell · doi:10.1111/j.1474-9728.2004.00097.x · Cited by 761
Telomerase and cancer therapeutics
Harley, C. B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2275 · Cited by 728 · cited 2×
“This inhibitor has been applied to breast cancers [40, 41], prostate cancers [42], glioblastoma [43], myeloma [44] and leukaemia [39].”
BackgroundMethodA Box H/ACA Small Nucleolar RNA-Like Domain at the Human Telomerase RNA 3′ End
Mitchell, J. R., Cheng, J., & Collins, K. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.567 · Cited by 510
Gomes, N. M. V., Ryder, O. A., Houck, M. L., Charter, S. J., Walker, W., Forsyth, N. R., Austad, S. N., Venditti, C., Pagel, M., Shay, J. W., et al. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00718.x · Cited by 464 · cited 1×
“This sequence length varies greatly across species, from approximately 300 base pairs to greater than 20 kb in length, and contains a 3′ G-rich single strand overhang [2–4].”
Background
Cited by
Chronic Kidney Disease: A Clinical Model of Premature Aging
Stenvinkel, P., & Larsson, T. E. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.11.051 · Cited by 296
Cell death mechanisms of plant-derived anticancer drugs: beyond apoptosis
Gali-Muhtasib, H., Hmadi, R., Kareh, M., Tohme, R., & Darwiche, N. (2015) · Apoptosis · doi:10.1007/s10495-015-1169-2 · Cited by 293
The Link between Chronic Stress and Accelerated Aging
Yegorov, Y. E., Poznyak, A. V., Nikiforov, N. G., Sobenin, I. A., & Orekhov, A. N. (2020) · Biomedicines · doi:10.3390/biomedicines8070198 · Cited by 147
Kaeberlein, M. (2013) · F1000Prime Reports · doi:10.12703/p5-5 · Cited by 112
Ascorbic Acid Attenuates Senescence of Human Osteoarthritic Osteoblasts
Burger, M., Steinitz, A., Geurts, J., Pippenger, B., Schaefer, D., Martin, I., Barbero, A., & Pelttari, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122517 · Cited by 25
“Alternatively, telomerase activation could be targeted with phytochemicals that demonstrated to rejuvenate ageing cells by counteracting senescence symptoms [60,61].”
Background
Metadata
- Authors
- Sprouse, A. A., Steding, C. E., & Herbert, B.
- Venue
- Journal of Cellular and Molecular Medicine
- Publisher
- Wiley
- Published
- 2011-12-29
- Volume
- 16
- Issue
- 1
- Pages
- 1-7
- ISSN
- 1582-1838 (ISSN-L)
- 1582-4934
- OpenAlex
- W1990630639
- Cited by
- 70
- References
- 12
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmaceutical regulation of telomerase and its clinical potential. https://app.cochat.ai/papers/10.1111/j.1582-4934.2011.01460.x
- The paper
- Sprouse, A. A., Steding, C. E., & Herbert, B. (2012). Pharmaceutical regulation of telomerase and its clinical potential. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/j.1582-4934.2011.01460.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.